Treatment of Refractory Infantile Spasms With Fenfluramine

Description

This is a phase II clinical trial in which children with refractory infantile spasms (also called epileptic spasms or West syndrome) will be treated with fenfluramine, to evaluate efficacy, safety, and tolerability. Patients with infantile spasms that have not responded to treatment with vigabatrin and ACTH we will be invited to participate. Study participants will undergo baseline video-EEG, receive treatment with fenfluramine for 21 days, and then undergo repeat video-EEG to determine effectiveness. Patients with favorable response will have the opportunity to continue treatment for up to 6 months.

Conditions

Infantile Spasm

Study Overview

Study Details

Study overview

This is a phase II clinical trial in which children with refractory infantile spasms (also called epileptic spasms or West syndrome) will be treated with fenfluramine, to evaluate efficacy, safety, and tolerability. Patients with infantile spasms that have not responded to treatment with vigabatrin and ACTH we will be invited to participate. Study participants will undergo baseline video-EEG, receive treatment with fenfluramine for 21 days, and then undergo repeat video-EEG to determine effectiveness. Patients with favorable response will have the opportunity to continue treatment for up to 6 months.

A Phase II Study of Fenfluramine for Treatment of Refractory Infantile Spasms

Treatment of Refractory Infantile Spasms With Fenfluramine

Condition
Infantile Spasm
Intervention / Treatment

-

Contacts and Locations

Los Angeles

UCLA Health, Los Angeles, California, United States, 90095

Orange

Children's Hospital of Orange County, Orange, California, United States, 92868

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Children ages 12 to 36 months, inclusive
  • * Clinical diagnosis of infantile spasms
  • * Continued epileptic spasms despite adequate treatment with ACTH and vigabatrin.
  • * Significant preexisting cardiovascular disease
  • * Exposure to any cannabinoid product within 14 days of screening
  • * Initiation or dose-titration of any second-line treatment for infantile spasms in the 14 days prior to screening.
  • * Implantation of a vagal nerve simulator within 14 days of screening
  • * Initiation and maintenance of the ketogenic diet within 3 months of screening

Ages Eligible for Study

12 Months to 36 Months

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Children's Hospital of Orange County,

Daniel Shrey, MD, PRINCIPAL_INVESTIGATOR, Children's Hospital of Orange County

Study Record Dates

2025-12-31